Latest market price
38.87
-0.31-0.79%
OverviewShort InterestFilings
NKTRQT12Nektar Therapeutics·NASDAQ
38.87-0.79%
News
Down 0.8% — Nektar Therapeutics: Focus Returns To The Strengths Of The Company (seekingalpha.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TRAX-0.33%$45.08NVAX-3.72%$10.08NUVB-0.21%$4.76KLRA-4.10%$12.86REPL+1.27%$17.61STOK-0.23%$26.29QURE-1.86%$24.83NTLA-5.74%$12.47
Snapshot
Index—P/E—EPS (ttm)-6.70Insider Own—Shs Outstand28.69MPerf Week4.43%
Market Cap1.12BForward P/E—EPS next Y-10.50Insider Trans-0.14%Shs Float29.14MPerf Month-17.28%
Enterprise Value567.10MPEG—EPS next Q-2.07Short Float24.01%Perf Quarter-44.94%
Income-158.00MP/S20.27EPS this Y—Short Ratio6.24Perf Half Y-55.04%
Sales55.00MP/B1.23EPS next Y—ROA-14.35%Short Interest7.00MPerf YTD-8.07%
Book/sh31.48P/C1.63EPS next 5Y—ROE-37.99%52W High109.00 -64.34%Perf Year-34.81%
Cash/sh23.84P/FCF—EPS past 3/5Y—ROIC-12.53%52W Low33.40 16.38%Perf 3Y423.15%
Dividend Est.—EV/EBITDA—Sales past 3/5Y-15.76% -18.50%Gross Margin99.36%Volatility3.29% 4.77%Perf 5Y-84.15%
Dividend TTM—EV/Sales10.31EPS Y/Y TTM—Oper. Margin-240.38%ATR (14)2.31Perf 10Y-81.15%
Dividend Ex-Date—Quick Ratio10.42Sales Y/Y TTM-25.68%Profit Margin-287.84%RSI (14)34.74Recom2.48
Dividend Gr. 3/5Y—Current Ratio10.42EPS Q/Q58.31%SMA200.37%Beta1.46Target Price121.33
Payout0.00%Debt/Eq0.15Sales Q/Q-9.09%SMA50-30.20%Rel Volume0.54Prev Close39.18
Employees63LT Debt/Eq0.13EarningsNov 12SMA200-40.21%Avg Volume1.11MPrice38.87
IPO DateMay 03, 1994Option/ShortYes / YesEPS/Sales Surpr.37.60% -2.82%Net Debt/EBITDA—Volume600,420Change-0.79%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-12-26InitiatedLeerinkOutperform$130
Oct-12-26ReiteratedUBS$53
Oct-01-26ReiteratedJefferiesBuy$121 → $150
Sep-23-26ReiteratedWedbushNeutral$80 → $50
Jul-22-26InitiatedCanaccordBuy$153
May-11-26ReiteratedWedbushNeutral$95 → $80
May-08-26ReiteratedPiper SandlerOverweight$105 → $192
Apr-21-26ReiteratedWedbushNeutral$95
Apr-20-26ReiteratedHC Wainwright & Co.Buy$165 → $185
Mar-13-26ReiteratedOppenheimerOutperform$115 → $140
Latest News· Times ET
Oct-30-26
Oct-30-2612:18PM
Nektar Therapeutics: Focus Returns To The Strengths Of The Companyseekingalpha.com
Oct-29-26
Oct-29-2611:06AM
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?zacks.com
Oct-27-26
Oct-27-2606:00PM
Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Marketsprnewswire.com
Oct-23-26
Oct-23-2604:15PM
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)prnewswire.com
Oct-16-26
Oct-16-2602:59AM
Maze Therapeutics (NASDAQ:MAZE) vs. Nektar Therapeutics (NASDAQ:NKTR) Financial Analysisdefenseworld.net
Oct-15-26
Oct-15-2601:35PM
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?zacks.com
Oct-07-26
Oct-07-2611:48AM
Cedar Grove Capital Q3 2026 Portfolio UpdateSeekingAlpha
Oct-03-26
Oct-03-2604:41AM
Nektar Therapeutics (NASDAQ:NKTR) Shares Gap Down – Here’s What Happeneddefenseworld.net
Oct-02-26
Oct-02-2604:08PM
Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And Moreseekingalpha.com
Oct-01-26
Oct-01-2612:50PM
Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcriptseekingalpha.com
12:03PM
Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trialmarketbeat.com
11:45AM
Nektar Stock Sinks Despite Promising Hair Loss Treatment Databarrons.com
11:44AM
3 Biotech Stocks Put Traders Are Targeting Todayschaeffersresearch.com
07:30AM
New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026prnewswire.com
04:29AM
Nektar Therapeutics (NASDAQ:NKTR) Stock Rated “Moderate Buy” by Sell-Side Brokeragesdefenseworld.net
Company

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue55559890—————
Cost of Goods Sold Incl. D&A003137—————
Gross Profit55556853—————
Selling, General and Administrative Excl. Other53697777—————
Research and Development132117121114—————
Other Operating Expense00-250—————
Operating Income-131-131-105-137—————
Interest Expense31262825—————
Unusual Expense
—————————
Non-Operating Income (Expense)5-714-113—————
Net Income Before Taxes-157-164-119-276—————
Income Taxes
0000—————
Consolidated Net Income-158-164-119-276—————
Net Income From Continuing Operations-157-164-119-276—————
Net Income-158-164-119-276—————
EPS (Recurring)-6.70-9.73-8.68-21.79—————
EPS (Basic, Before Extraordinaries)-6.70-9.73-8.68-21.79—————
EPS (Diluted)-6.70-9.73-8.68-21.79—————
EBITDA-134-137-87-243—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio23.3213.071.991.22—————
Gross Margin100.00100.0069.3958.89—————
Operating Margin-238.18-238.18-107.14-152.22—————
Net Margin-287.27-298.18-121.43-306.67—————
Shares Outstanding33171413—————
Market Capitalization1,283719195110—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$111.35$87.52$63.69$39.86$16.03● Close Price0.00M0.49M0.97M1.46M1.95MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Zalevsky JonathanChief R&D OfficerAug 18 '26Sale71.9818613,3889,570Aug 20
ROBIN HOWARD WPresident & CEOAug 18 '26Sale71.9841830,08854,627Aug 20
Zalevsky JonathanChief R&D OfficerJun 30 '26Sale70.005,681397,6709,756Jul 02
ROBIN HOWARD WPresident & CEOJun 17 '26Sale61.1910,000611,88055,045Jun 18
ROBIN HOWARD WPresident & CEOJun 16 '26Sale60.3210,000603,17665,045Jun 18
Zalevsky JonathanChief R&D OfficerJun 15 '26Sale60.715,538336,21215,437Jun 17
Zalevsky JonathanChief R&D OfficerMay 19 '26Sale65.5119913,03620,975May 21
ROBIN HOWARD WPresident & CEOMay 19 '26Sale65.5144429,08675,045May 21
Zalevsky JonathanChief R&D OfficerFeb 18 '26Sale73.0018013,14021,174Feb 20
ROBIN HOWARD WPresident & CEOFeb 18 '26Sale73.0042330,87975,489Feb 20
Zalevsky JonathanChief R&D OfficerJan 20 '26Sale35.673,867137,93621,354Jan 22
Zalevsky JonathanChief R&D OfficerNov 25 '25Sale54.281,15762,80218,971Nov 25
Wilson Mark AndrewChief Legal OfficerNov 25 '25Sale54.2863034,19621,585Nov 25
ROBIN HOWARD WPresident & CEONov 25 '25Sale54.282,207119,79654,245Nov 25
ROBIN HOWARD WPresident & CEOSep 09 '25Sale46.696,666311,21449,342Sep 11
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.